PBR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Petroleo Brasileiro SA Petrobras (PBR) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators are bullish and the financial performance shows modest growth, the lack of significant positive catalysts, recent analyst downgrades, and the neutral sentiment from hedge funds and insiders suggest that the stock does not present a compelling entry point right now. Additionally, the absence of strong proprietary trading signals further supports a cautious approach.
The technical indicators for PBR are bullish. The MACD is positive and expanding, the RSI is neutral at 77.395, and the moving averages show a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with resistance at R1: 16.523 and R2: 16.977. However, the stock's candlestick pattern analysis suggests a mixed short-term outlook, with a 50% chance of a 4.7% gain in the next day but potential declines of -7.02% in the next week and -5.56% in the next month.
The company's financials for Q3 2025 show modest growth, with revenue up 0.48% YoY, net income up 2.27% YoY, and EPS up 2.17% YoY. Additionally, the stock's technical indicators are currently bullish.
Recent analyst downgrades from Bradesco BBI and BTG Pactual, with reduced price targets of $17 and $15 respectively, indicate a lack of confidence in the stock's near-term performance. Hedge funds and insiders are neutral, showing no significant trading activity. Furthermore, there is no recent news or congress trading data to act as a catalyst.
In Q3 2025, Petroleo Brasileiro SA Petrobras reported revenue of $23.48 billion, up 0.48% YoY. Net income increased to $6.00 billion, up 2.27% YoY, and EPS rose to 0.47, up 2.17% YoY. However, gross margin dropped to 41.63%, down -10.82% YoY, which could indicate some operational challenges.
Recent analyst activity has been negative, with Bradesco BBI and BTG Pactual downgrading the stock to Neutral from Outperform and Buy, respectively. The price targets have also been reduced, with the highest at $17 and the lowest at $15, reflecting limited upside potential.
